跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 60,281 条关于
“Knight Therapeutics Inc.”
全部
60,281
临床试验
22,816
药物
4,533
机构
6,587
资讯
26,345
去年
Knight Therapeutics Acquires Sumitomo's Canadian Portfolio Including MYFEMBREE and ORGOVYX for C$25.4 Million
去年
TAVALISSE® (Fostamatinib) Approved in Mexico for Chronic ITP Treatment
去年
Knight Therapeutics Seeks Approval for Qelbree® (viloxazine) in Canada for ADHD Treatment
去年
Knight Therapeutics to Acquire Paladin in $120 Million Strategic Pharmaceutical Deal
10个月前
Knight Therapeutics Launches First Evening-Dosed ADHD Treatment JORNAY PM in Canada
去年
Knight Therapeutics Submits MINJUVI Supplemental Application for Follicular Lymphoma in Brazil
去年
Knight Therapeutics Files New Drug Submission for CREXONT in Canada Following Successful Phase 3 Trial
去年
60 Degrees Pharmaceuticals Seeks FDA MUMS Designation for First Oral Canine Babesiosis Treatment
去年
Knight Therapeutics Launches Minjuvi for Relapsed/Refractory DLBCL in Mexico
22天前
Knight Therapeutics Submits Supplemental Application to ANVISA for First-Line MINJUVI (tafasitamab) in DLBCL and HGBL
第 1 页,共 2635 页
上一页
下一页